בית › סרטן הלבלב › מסצ'וסטס › Boston
מחקרים קליניים עבור סרטן הלבלב ב-Boston, MA
43 מחקרים עבור סרטן הלבלב מחפשים משתתפים באתרים ב-Boston ובסביבתה (בטווח של כ-30 מייל). פתחו מחקר כדי לראות מי יכול להשתתף וכיצד ליצור קשר עם צוות המחקר.
טקסט רשמי של המחקר (באנגלית)
מגייסים משתתפים למחקר כאן? הציגו אותו בראש העמוד – $99 ל-30 ימים →
Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
מגייסשלב 1/2
- Research Site, Boston
Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Changes in the HER2 Gene
מגייסשלב 1
- Dana-Farber Cancer Institute, Boston
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
מגייסשלב 1
- Massachusetts General Hospital, Boston
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
מגייסשלב 2
- Dana-Farber Cancer Institute - Oncology Department, Boston
Distance-Based Exercise to Preserve Function and Prevent Disability
מגייס
- Dana-Farber Cancer Institute, Boston
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
מגייסשלב 1
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
A Study of PHN-012 in Patients With Advanced Solid Tumors
מגייסשלב 1
- PHN-012-001 Site, Boston
Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )
מגייסשלב 3
- Dana Farber Cancer Institute, Boston
Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)
מגייסשלב 3
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute (DFCI), Boston
A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma
מגייסשלב 3
- Investigative Site US022, Boston
Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
מגייסשלב 1/2
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
מגייסשלב 1/2
- Dana Farber Cancer Institute, Boston
Pancreatic Cancer Detection Consortium (PCDC) Prospective Cohorts
מגייסמחקר תצפיתי
- Dana-Farber Cancer Institute, Boston
A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations
מגייסשלב 1/2
- Massachusetts General Hospital - Main Campus, Boston
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
מגייסשלב 1
- Dana-Farber Cancer Institute, Boston
A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
מגייסשלב 2
- Local Institution - 0124, Boston
Biospecimen Collection to Identify Gene Mutations for High Risk Pancreatic Cancer in Pediatric Patients, INSPPIRE 2 Study
מגייסמחקר תצפיתי
- Boston Children's Hospital, Boston
Resilience and Equity in Aging, Cancer, and Health (REACH)
מגייס
- Dana-Farber Cancer Institute, Boston
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer
מגייסשלב 2
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Pancreatic Cancer Early Detection Consortium
מגייסמחקר תצפיתימתנדבים בריאים מוזמנים
- Massachusetts General Hospital, Boston
A Study of PT0511 in Participants With KRAS Mutated or Amplified Advanced Solid Tumors
מגייסשלב 1
- Dana-Farber/Massachusetts General Hospital, Inc, Boston
A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation
מגייסשלב 1
- Mass General Brigham Cancer Institute at Massachusetts General Hospital, Boston
A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
מגייסשלב 1
- Research Site, Boston
- Research Site, Boston
Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation
מגייסשלב 1
- Dana Farber Cancer Institute, Boston
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
מגייסשלב 1
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Prospective Screening for Pancreatic Ductal Adenocarcinoma in High-Risk Individuals
מגייסשלב 1 מוקדםמתנדבים בריאים מוזמנים
- Brigham and Women's Hospital, Boston
- Dana Farber Cancer Institute, Boston
Video Education With Result Dependent dIsclosure
מגייס
- Dana Farber Cancer Institute, Boston
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
מגייסשלב 1/2
- Dana Farber Cancer Institute, Boston
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
מגייסשלב 1/2
- Massachusetts General Hospital, Boston
A Study of MGC028 in Participants With Advanced Solid Tumors
מגייסשלב 1
- Mass General Brigham, Boston
- Dana Farber/Harvard Cancer Center, Boston
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
מגייסשלב 1/2
- Massachusetts General Hospital, Boston
Acoustic Cluster Therapy (ACT) With Chemotherapy for the Treatment of Locally Advanced Pancreatic Cancer
מגייסשלב 2
- Beth Israel Deaconess Medical Center - Division of Hematology/Oncology, Boston
A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors
מגייסשלב 1/2
- Dana-Farber Cancer Institute, Boston
Evaluation of PET Probe [68Ga]CBP8 in the Detection of Radiation Induced Tissue Injury
מגייסשלב 2
- Massachusetts General Hospital, Boston
Resistance Exercise Combined With Protein Supplementation in People With Pancreatic Cancer: The RE-BUILD Trial
מגייס
- Dana Farber Cancer Institute, Boston
A Phase II Nationwide, Fully Decentralized, Telemedicine Study of Pemigatinib in Adult Patients With Advanced or Metastatic Pancreatic Cancer With FGFR Genetic Alterations
מגייסשלב 2
- Ohio State University-Telemedicine, Boston
The Effect of Kinisoquin™ on Thromboembolic Events in Patients With Metastatic or Locally Advanced Pancreatic Cancer
מגייסשלב 3
- Beth Israel Deaconess Medical Center, Boston
Feasibility of the LUM Imaging System for Detection of Gastrointestinal Cancers
מגייסשלב 1/2
- Massachusetts General Hospital, Boston
Stereotactic Magnetic Resonance Guided Radiation Therapy
מגייס
- Brigham & Women's Hospital, Boston
- Dana Farber Cancer Institute, Boston
The Cancer of the Pancreas Screening-5 CAPS5)Study
מגייסשלב 3
- Dana Farber Cancer Center, Harvard University, Boston
A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors
מגייסשלב 1/2
- Dana Farber Cancer Institute, Boston
Confocal Laser Endomicroscopy as an Imaging Biomarker for the Diagnosis of Pancreatic Cystic Lesions
מגייסמחקר תצפיתי
- Beth Israel Deaconess Medical Center, Boston
Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors
מגייסשלב 1
- Dana Farber/Partners Cancer Care Inc, Boston
מחקרים עבור סרטן הלבלב בערים אחרות
- Houston, TX61 מחקרים
- New York City, NY60 מחקרים
- Nashville, TN39 מחקרים
- Los Angeles, CA35 מחקרים
- St. Louis, MO33 מחקרים
- Arlington, VA33 מחקרים
- Baltimore, MD31 מחקרים
- San Antonio, TX31 מחקרים
- Philadelphia, PA26 מחקרים
- Tampa, FL26 מחקרים
- Durham, NC24 מחקרים
- San Diego, CA24 מחקרים
מחקרים אחרים ב-Boston
- סרטן השד112 מחקרים
- סרטן ריאות לא תא קטן90 מחקרים
- סרטן (כל הסוגים)85 מחקרים
- סרטן גרורתי63 מחקרים
- סרטן המעי הגס והחלחולת63 מחקרים
- סרטן הריאה62 מחקרים
- סרטן השחלות61 מחקרים
- סרטן הערמונית59 מחקרים
- דיכאון52 מחקרים
- סרטן אנדומטריאלי50 מחקרים
- אי-ספיקת לב44 מחקרים
- לוקמיה מיאלואידית חריפה44 מחקרים
מקור: ClinicalTrials.gov, המידע אוחזר בתאריך 6 באוק׳ 2026. כל מחקר מגדיר את קריטריוני ההשתתפות שלו; צוות המחקר קובע מי יכול להשתתף.